Vestal Point Capital, LP
Q4 2025 13F Holdings
- Locationnew york, NY
- Num holdings
76
- Value ($000)
$2,941,274
- Date Filed02/17/2026
- Form type13F-HR
- CIK0001974915
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
Abivax SA | SPONSORED ADS | 00370M103 | $256.22M | 9 % | 1,900,000 | ||
Invesco QQQ Trust Series 1 | UNIT SER 1 | 46090E103 | $215.01M | 7 % | 350,000 | put | |
Arcellx Inc | COMMON STOCK | 03940C100 | $190.71M | 7 % | 2,925,000 | ||
Terns Pharmaceuticals Inc | COM | 880881107 | $181.8M | 6 % | 4,500,000 | ||
BioMarin Pharmaceutical Inc | COM | 09061G101 | $178.29M | 6 % | 3,000,000 | ||
Globus Medical Inc | CL A | 379577208 | $111.32M | 4 % | 1,275,000 | ||
Nurix Therapeutics Inc | COM | 67080M103 | $88.97M | 3 % | 4,690,000 | ||
Alcon AG | ORD SHS | H01301128 | $87.09M | 3 % | 1,105,000 | ||
Dexcom Inc | COM | 252131107 | $84.62M | 3 % | 1,275,000 | ||
Merck & Co Inc | COM | 58933Y105 | $81.58M | 3 % | 775,000 |
Rows Per Page
10
- 5
- 10
- 20
- 30
- 50
- 100